CA3249922A1 - OPHTHALMIC TOPICAL CREAM COMPOSITIONS - Google Patents
OPHTHALMIC TOPICAL CREAM COMPOSITIONSInfo
- Publication number
- CA3249922A1 CA3249922A1 CA3249922A CA3249922A CA3249922A1 CA 3249922 A1 CA3249922 A1 CA 3249922A1 CA 3249922 A CA3249922 A CA 3249922A CA 3249922 A CA3249922 A CA 3249922A CA 3249922 A1 CA3249922 A1 CA 3249922A1
- Authority
- CA
- Canada
- Prior art keywords
- therapeutic treatment
- treatment composition
- ophthalmic therapeutic
- ophthalmic
- api
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263363356P | 2022-04-21 | 2022-04-21 | |
| US63/363,356 | 2022-04-21 | ||
| PCT/US2023/065956 WO2023205695A1 (en) | 2022-04-21 | 2023-04-19 | Ophthalmic topical cream compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3249922A1 true CA3249922A1 (en) | 2023-10-26 |
Family
ID=86558713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3249922A Pending CA3249922A1 (en) | 2022-04-21 | 2023-04-19 | OPHTHALMIC TOPICAL CREAM COMPOSITIONS |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12414938B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4511001A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025513344A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119584954A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023257375A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3249922A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023205695A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026060434A1 (en) * | 2024-09-16 | 2026-03-19 | Iview Therapeutics, Inc. | Novel eyelid delivery of ophthalmic composition containing muscarinic receptor modulators for prevention and treatment of ocular disorders |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2752008T3 (es) | 2009-10-30 | 2020-04-02 | Intratus Inc | Métodos y composiciones para la liberación sostenida de fármacos |
| US20120195969A1 (en) | 2010-09-29 | 2012-08-02 | Aidan Research And Consulting, Llc | Treatment of acne by conditioned media |
| DK2645993T3 (en) | 2010-12-03 | 2017-02-13 | Allergan Inc | Pharmaceutical cream compositions comprising oxymetazoline |
| BR112015031885A2 (pt) | 2013-06-18 | 2017-07-25 | Lubrizol Advanced Mat Inc | dispersões estáveis coloidalmente com base em galactomananas modificadas |
| CN113559105B (zh) | 2014-01-29 | 2026-06-23 | 维奥姆治疗有限公司 | 抗性痤疮的治疗 |
| US20170266289A1 (en) * | 2014-08-27 | 2017-09-21 | Abbvie Inc. | Topical formulation |
| US20170087199A1 (en) | 2016-02-10 | 2017-03-30 | Senomyx, Inc. | Compositions for delivering a cooling sensation |
| CA3032695C (en) * | 2016-08-19 | 2021-11-23 | Akrivista, LLC | Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye |
| US11160780B2 (en) * | 2016-09-30 | 2021-11-02 | Aurobindo Pharma Ltd. | Pharmaceutical composition of ivermectin and process for preparation thereof |
| JP6946575B2 (ja) | 2018-04-24 | 2021-10-06 | アラーガン、インコーポレイテッドAllergan,Incorporated | 眼の状態の治療のためのピロカルピン塩酸塩の使用 |
| DK3870170T3 (da) * | 2018-10-26 | 2026-05-26 | Opus Genetics Inc | Behandling af presbyopi og mydriasis med fentolamin |
| WO2020141482A1 (en) * | 2019-01-04 | 2020-07-09 | Glenmark Specialty S.A. | Pharmaceutical compositions comprising mupirocin |
| NZ781774A (en) * | 2019-03-08 | 2023-03-31 | Taro Pharma Ind | Stable topical compositions of fenoldopam |
| US20220071924A1 (en) * | 2019-03-19 | 2022-03-10 | Sol-Gel Technologies Ltd. | Treatment of ocular diseases with ophthalmic tapinarof compositions |
| WO2024026365A1 (en) | 2022-07-26 | 2024-02-01 | Glaukos Corporation | Ophthalmic topical cream formulations and uses thereof |
-
2023
- 2023-04-19 AU AU2023257375A patent/AU2023257375A1/en active Pending
- 2023-04-19 EP EP23726255.5A patent/EP4511001A1/en active Pending
- 2023-04-19 WO PCT/US2023/065956 patent/WO2023205695A1/en not_active Ceased
- 2023-04-19 JP JP2024561808A patent/JP2025513344A/ja active Pending
- 2023-04-19 CA CA3249922A patent/CA3249922A1/en active Pending
- 2023-04-19 CN CN202380041605.2A patent/CN119584954A/zh active Pending
- 2023-04-20 US US18/304,263 patent/US12414938B2/en active Active
-
2025
- 2025-08-22 US US19/307,927 patent/US20250387372A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025513344A (ja) | 2025-04-24 |
| WO2023205695A1 (en) | 2023-10-26 |
| US20230381145A1 (en) | 2023-11-30 |
| US20250387372A1 (en) | 2025-12-25 |
| EP4511001A1 (en) | 2025-02-26 |
| US12414938B2 (en) | 2025-09-16 |
| AU2023257375A1 (en) | 2024-11-07 |
| CN119584954A (zh) | 2025-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230372303A1 (en) | Applications of zwitterions in ophthalmic topical cream compositions and preparations | |
| KR101809713B1 (ko) | 방부제 없는 프로스타글란딘계 비점성 용액의 고분자 전달 시스템 | |
| JP5705552B2 (ja) | 眼痛を処置または防止するためのケトロラックトロメタミン組成物 | |
| WO2004058273A1 (en) | Use of rimexolone in the treatment of dry eye | |
| TW201105363A (en) | Eye drop for macular edema treatment | |
| US20250387372A1 (en) | Ophthalmic topical cream compositions and methods | |
| US5929115A (en) | Anti-inflammatory eye drop | |
| EP0517160B1 (en) | Extended-release ophthalmic preparations | |
| WO2013043387A1 (en) | Ophthalmic gel compositions | |
| JP2017501184A (ja) | 低減された眼圧で術後の炎症を治療するための方法 | |
| KR101723703B1 (ko) | 안구 통증을 치료 또는 예방하기 위한 케토롤락 트로메타민 조성물 | |
| US5443833A (en) | Pharmaceutical compositions | |
| JP4263418B2 (ja) | 熱ゲル化人工涙液 | |
| JP2025513344A5 (cg-RX-API-DMAC7.html) | ||
| JPS63502270A (ja) | 散瞳作用を有する眼科用医薬組成物 | |
| JPWO2020138135A1 (ja) | 眼科用組成物 | |
| USRE38628E1 (en) | Pharmaceutical compositions | |
| KR100261585B1 (ko) | 항염증점안제 | |
| CN116270442A (zh) | 一种用于矫正近距离视力的眼用制剂 | |
| US20170128481A9 (en) | Ocular treatment with reduced intraocular pressure | |
| Mali et al. | IN SITU GEL-FORMING SYSTEMS | |
| HK1178446B (en) | Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives | |
| HK1201464B (en) | Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives | |
| HK1149212B (en) | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241021 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250113 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250113 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250113 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250114 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250410 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250410 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260415 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260415 |